Download Free Sample
Buy Now
Market Size
The next generation drug conjugates market, valued at USD 8.0 billion in 2025, is projected to reach USD 11.2 billion in 2026 and USD 26.2 billion by 2035, representing a CAGR of 9.9% during the forecast period 2026 to 2035.
See What’s in the Full Report – Request Your Complimentary Insights!
Market Report: Key Takeaways
- In terms of type of drug conjugate, ligand mediated RNAi conjugates hold the highest share (around 55%) of the current market.
- With respect to type of targeting ligand, next generation drug conjugates with amino sugar dominate (more than 60%) the current market.
- Based on the type of payload, siRNAs containing next generation drug conjugate therapy programs capture the largest share (around 55%) of the current market; this trend is unlikely to change in the future.
- Amongst the route of administration, next generation drug conjugates that can be administered subcutaneously capture most (>60%) of the current market.
- In terms of type of therapy, currently, drug conjugates given as monotherapy capture majority (~95%) of the market.
- Based on the therapeutic area, XDCs targeting genetic disorders are likely to generate majority of the revenues (~40%) in the current next generation drug conjugates market.
- In terms of geographical regions, North America currently holds the highest market share (close to 70%). This can be attributed to its strong public and private investments, supportive regulations, and significant funding initiatives to propel regional market growth.
Market Overview
Next generation drug conjugates (XDCs) incorporate a wide range of payloads, linkers, and targeting modalities, which enables highly selective delivery of therapeutic agents to diseased tissues or sites while minimizing off-target side effects. Further, with the integration of advanced chemical engineering procedures, modern design strategies, and specific targeting modalities, next generation drug conjugates enhance the therapeutic window and potency, allowing developers to create more advanced and site-targeted therapeutic options.
The next generation drug conjugates landscape is expanding rapidly, driven by the ongoing innovations in payload types, which include oligonucleotides, peptides, and small molecules, linker optimization, and conjugation platforms that improve stability and controlled release. Despite this progress, the field still faces significant challenges related to payload–target compatibility, scalable manufacturing, and physicochemical complexity.
The rising applicability of XDCs across oncology, rare diseases, and immune-mediated disorders, combined with accelerated investments in precision and multimodal therapeutics, is driving strong momentum and positioning next generation drug conjugates as a transformative segment within the conjugate therapeutics market.
Recent Developments
- In March 2026, Avacta dosed the first patient in its Phase 1 FOCUS-01 clinical trial of AVA6103, a peptide drug conjugate designed to deliver a potent exatecan payload to the tumor microenvironment using pre-CISION® technology. This advancement represents a significant step in developing targeted therapies for solid tumors, aiming to maximize antitumor efficacy while reducing systemic toxicity.
- In February 2026, OliX Pharmaceuticals, a leading developer of RNAi therapeutics, entered into an agreement with Vect-Horus, a biotechnology company, to evaluate the potential of Vect-Horus BBB shuttle–siRNA technology (VECTrans®) to deliver siRNAs into the central nervous system.
- In January 2026, DAWNZERA™ (donidalorsen), a ligand mediated conjugate, was approved by the European Union for prophylactic treatment of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents.
Your Business is Unique – Why Shouldn’t Your Report Be?
Next Generation Drug Conjugates Market Trends
- Increased Clinical Trial Activity: Currently close to 220 clinical trials are ongoing / completed in the next generation drug conjugates domain. Nearly 80% of these trials are in the early phase of development. Interestingly, majority of these clinical trials are being initiated in North America, followed by Europe.
- Partnerships and Collaborations: This domain is witnessing several partnerships, which are likely to drive the next generation drug conjugates market growth. It is important to highlight that most of the players have inked international agreements (60%). Further, Alnylam Pharmaceuticals emerged as the leading player having signed the maximum number of deals, with 29% focused on hepatic disorders.
- Academic Grant Analysis: Since 2018, more than 160 grants have been awarded to various institutes advancing research and development in this domain. It is worth highlighting that close to 70% of grants were allocated for non-small business innovative research / small business technology transfer research. Further, NCI (National Cancer Institute), NIAID (National Institute of Allergy and Infectious Diseases), NIGMS (National Institute of General Medical Sciences) and NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) emerged as the most popular funding institutes.
- Recent Publications: More than 240 articles related to next generation drug conjugates have been published since 2020. This trend is largely driven by the ongoing technological innovations in structural components of such conjugates (including stable linkers and highly potent payloads). These innovations have unlocked promising new research avenues, demanding extensive research efforts across the domain.
- Drug Failure Analysis: Several next generation drug conjugates have been discontinued / terminated in last few years. Notably, 60% of these were discontinued during phase II trials due to safety concerns, sponsors decisions and strategic / business decisions.
- Success Protocol Analysis: Given the recent advancements in the conjugation domain, stakeholders involved in the development of next generation conjugates evaluate several critical factors that contribute significantly in the success of the therapy program. It is worth highlighting that the success of a next generation drug conjugate is influenced by its novelty, efficacy, price and dosage regimen. Further, the prevailing market competition determines the overall outreach of the therapy program.
Industry Experts on Next Generation Drug Conjugates Market
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:
- Doctor of Medicine, Large Organization, Canada, North America
- Doctor of Medicine, PhD, Large Organization, Spain, Europe
- Vice President of Biologics Engineering and Tumor-Targeted Delivery, Large Organization, Europe
- Surgical Oncologist, Cancer Research Organization, Denver, North America
- Doctor of Medicine, Cancer Research Organization, US, North America
- Chief Executive Officer, Large Organization, UK, Europe
Market Drivers
- Enhanced Precision: Ongoing advancements in linker stability, payload potency, and targeted delivery mechanisms are enhancing the therapeutic index of XDCs. These innovations allow scientists to achieve higher tumor-killing efficacy while minimizing damage to healthy tissues. This precision approach is fueling new strategies in oncology for treating both hematologic malignancies and solid tumors.
- Payload Innovation: The growing interest in delivering RNA-based therapeutics through next generation drug conjugate formats is driving innovation in oligonucleotide payload chemistry, stability, and controlled-release systems. As developers refine these payloads to enhance intracellular delivery and reduce immunogenicity, XDCs are emerging as a promising modality for precision gene regulation and targeted genetic intervention.
- Hybrid Conjugate Breakthrough: Next generation hybrid XDCs that combine multiple payload classes, such as small molecules, peptides, and oligonucleotides, are gaining traction due to their ability to modulate complex disease pathways. Moreover, emerging platforms now support dual-mechanism or multi-mechanism payload strategies without compromising stability, positioning XDCs as a transformative therapeutic class capable of overcoming traditional monotherapy limitations.
Pay Only for What You Need – The Best Way to Optimize
Market Segmentation Analysis
Ligand mediated RNAi Conjugates Growth Driving Cancer Therapy Development
- According to the next generation drug conjugates market forecast, the ligand mediated RNAi conjugates sub-segment dominates the market (around 55%), driven by the increased demand for therapies with better and enhanced efficacy and safety profile.
- Virus-like drug conjugates are likely to grow at a higher CAGR, showcasing substantial market growth potential during the forecast period. This growth is due to their ability to mimic natural viral entry pathways and achieve highly efficient intracellular delivery.
Subcutaneously Administered XDCs to Drive Growth in Next Generation Drug Conjugates Market
- According to our market forecast, across different routes of administration, the subcutaneous sub-segment accounts for more than 60% of the current market revenues.
- This results from its ease of administration, improved patient adherence, and reduced dependence on hospital-based procedures, coupled with the rising prevalence of cancer, advancements in oncology precision medicine and growing investments in research and development in this domain.
Next Generation Drug Conjugate Monotherapies are Likely to Dominate the Current Market
- According to the next generation drug conjugates market forecast, the majority (~95%) of next generation drug conjugates are prescribed as monotherapy. Moreover, it is important to highlight that this trend is unlikely to change in the future as well.
- This is due to their simplified dosing and reduced toxicity, making them attractive for long-term management of target indications and personalized medicines. Also, one of the major drivers for the growth of this segment is the approval of XDCs, notable examples of monotherapies approved post-2022 include GIVLAARI® / givosiran, OXLUMO® / lumasiran, Leqvio® / inclisiran, AMVUTTRA® / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02, AAA617 / PLUVICTO® / Lutetium Lu 177 vipivotide tetraxetan and Illuccix® (68Ga-PSMA-11).
Market Regional Insights
North America Dominates the Market
In 2035, North America’s next generation drug conjugates market will likely dominate, capturing more than 55% of the overall market share. Key factors that contribute to the region’s dominance in this industry include robust partnerships between academia and industry, cutting-edge manufacturing capabilities for potent conjugates and comprehensive intellectual property activity. Notable XDCs approved in the region include GIVLAARI® (givosiran), DAWNZERA™ / donidalorsen, TRYNGOLZA® / olezarsen, WAINZUA / Eplontersen and Lutathera. Moreover, it is worth highlighting that Lutathera generated net sales worth USD 0.8 billion in 2025.
Next Generation Drug Conjugates Adoption in the European Region
The next generation drug conjugates market in Europe is likely to grow at a high CAGR (~14%), during the forecast period. Notable examples of very large companies providing next generation drug conjugates based in Europe, include Novartis, Novo Nordisk, AstraZeneca and Bayer. The detailed methodology across the global market and revenue generated across various segments is available in the full report.
Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed
Next Generation Drug Conjugates Market: Scope of the Report
| Key Report Attributes | Details | |
| Historical Trend | Since 2023 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | USD 11.2 Billion | |
| Market Size 2035 | USD 26.2 Billion | |
| CAGR (Till 2035) | 9.9% | |
| Key Players Profiled |
|
|
| Segments Covered |
|
|
| Excel Data Packs (Complimentary) |
|
|
| PowerPoint Presentation (Complimentary) |
|
|
| Customization Scope |
|
|
Market Segments
Based on the research, we have segmented the next generation drug conjugates market into type of drug conjugate, type of targeting ligand, type of payload, route of administration, type of therapy, therapeutic area and geographical regions.
By Type of Drug Conjugate
- Ligand Mediated RNAi Conjugates
- Ligand Conjugated Antisense Medicines
- Peptide-Radionuclide Conjugates
- Small Molecule Drug Conjugates
- Virus-like Drug Conjugates
- Radioconjugates
By Type of Targeting Ligand
- Amino Sugars
- Peptides
- Lipids
- Virus-like Particles
- Others
By Type of Payload
- siRNAs
- Radionuclides
- Antisense Oligonucleotides
- Drugs
- Others
By Route of Administration
- Subcutaneous
- Intravenous
- Suprachoroidal
- Others
By Type of Therapy
- Monotherapies
- Combination Therapies
- Others
By Therapeutic Area
- Genetic Disorders
- Oncological Disorders
- Metabolic Disorders
- Cardiovascular Disorders
- Autoimmune Disorders
- Hematological Disorders
- Renal Disorders
- Hepatic Disorders
By Geographical Regions
- North America
- US
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Brazil
- Argentina
- Saudi Arabia
